Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open‐Label, Single‐Arm, Phase II Study
Journal of Obstetrics and Gynaecology Research · 2026
DOI: 10.1111/jog.70292 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Feng Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, …. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Neoplasm Recurrence, Local, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Aim
To evaluate the efficacy and safety of pamiparib monotherapy in recurrent ovarian cancer (rOC) after prior PARPi exposure.
Methods
This was a prospective clinical trial. Fifteen patients were enrolled between August 2022 and December 2023. Oral pamiparib 60 mg twice daily was administered until conditions specified in the protocol. Primary endpoint was clinical benefit rate ≥ 4 months (CBR4m; percentage of patients who sustained complete response, partial response [PR], and stable disease for at least 4 months). Secondary endpoints included progression‐free survival (PFS), overall response rate (ORR), overall survival (OS), and safety.
Results
Median number of previous treatment line was 3 (range, 2–6). CBR4m was 26.7% and the study was halted in the first stage according to the pre‐set statistical criteria. Two patients achieved PR for an ORR of 13.3%. With a median follow‐up of 16.1 months, median PFS and OS were respectively 2.8 (95% confidence interval [CI], 1.6–NR) and 15.6 (95% CI, 8.4–NR) months. Subgroup analyses showed CBR4m of 37.5% (3/8) in BRCAmut and 14.3% (1/7) in BRCAwt cohorts. CA‐125 response according to GCIG criteria was observed in 26.7% of patients. There were no treatment‐related serious adverse events or deaths.
Conclusions
Pamiparib monotherapy preliminarily showed limited efficacy and acceptable safety profiles in heavily pretreated rOC after prior PARPi exposure. The results suggested that single‐agent pamiparib retreatment may not be an effective treatment for this patient population; further investigation of combining PARPi with agents with different mechanisms may be warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.
ORCID-Profile: Guangyi Jiang, Jianqing Zhu
Förderung
- Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Cheng, F., Sun, L., Shao, F., Yang, L., Jiang, G., & Zhu, J. (2026). Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open‐Label, Single‐Arm, Phase II Study. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70292
Vancouver
Cheng F, Sun L, Shao F, Yang L, Jiang G, Zhu J. Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open‐Label, Single‐Arm, Phase II Study. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70292
BibTeX
@article{Cheng2026,
author = {Cheng, Feng and Sun, Lu and Shao, Feng and Yang, Li and Jiang, Guangyi and Zhu, Jianqing},
title = {Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open‐Label, Single‐Arm, Phase II Study},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2026},
doi = {10.1111/jog.70292}
}
EUVIMED